全文获取类型
收费全文 | 2781篇 |
免费 | 416篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 74篇 |
妇产科学 | 324篇 |
基础医学 | 230篇 |
口腔科学 | 44篇 |
临床医学 | 1022篇 |
内科学 | 344篇 |
皮肤病学 | 53篇 |
神经病学 | 118篇 |
特种医学 | 268篇 |
外科学 | 199篇 |
综合类 | 78篇 |
一般理论 | 1篇 |
预防医学 | 197篇 |
眼科学 | 28篇 |
药学 | 136篇 |
肿瘤学 | 84篇 |
出版年
2023年 | 50篇 |
2021年 | 18篇 |
2020年 | 42篇 |
2019年 | 34篇 |
2018年 | 72篇 |
2017年 | 103篇 |
2016年 | 95篇 |
2015年 | 115篇 |
2014年 | 137篇 |
2013年 | 144篇 |
2012年 | 101篇 |
2011年 | 108篇 |
2010年 | 138篇 |
2009年 | 129篇 |
2008年 | 96篇 |
2007年 | 105篇 |
2006年 | 93篇 |
2005年 | 66篇 |
2004年 | 67篇 |
2003年 | 78篇 |
2002年 | 64篇 |
2001年 | 58篇 |
2000年 | 35篇 |
1999年 | 54篇 |
1998年 | 100篇 |
1997年 | 117篇 |
1996年 | 112篇 |
1995年 | 108篇 |
1994年 | 68篇 |
1993年 | 57篇 |
1992年 | 30篇 |
1991年 | 44篇 |
1990年 | 34篇 |
1989年 | 57篇 |
1988年 | 53篇 |
1987年 | 31篇 |
1986年 | 47篇 |
1985年 | 47篇 |
1984年 | 19篇 |
1983年 | 27篇 |
1982年 | 30篇 |
1981年 | 20篇 |
1980年 | 24篇 |
1979年 | 12篇 |
1978年 | 25篇 |
1977年 | 20篇 |
1976年 | 17篇 |
1975年 | 20篇 |
1972年 | 8篇 |
1970年 | 8篇 |
排序方式: 共有3205条查询结果,搜索用时 390 毫秒
91.
Dual endothelin‐1 receptor antagonism attenuates platelet‐mediated derangements of blood coagulation in Eisenmenger syndrome
下载免费PDF全文
![点击此处可从《Journal of thrombosis and haemostasis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
B. Kevane S. Allen K. Walsh K. Egan P. B. Maguire M. C. Galligan D. Kenny R. Savage E. Doran Á. Lennon E. Neary F. Ní Áinle 《Journal of thrombosis and haemostasis》2018,16(8):1572-1579
Essentials
- Eisenmenger syndrome is characterised by thrombotic and hemorrhagic risks of unclear aetiology.
- Calibrated automated thrombography was used to assess these coagulation derangements.
- Platelet activity supported abnormalities in procoagulant and anticoagulant pathway function.
- Endothelin‐1 antagonism appeared to ameliorate these derangements.
Summary
Aims
The mechanisms underlying the competing thrombotic and hemorrhagic risks in Eisenmenger syndrome are poorly understood. We aimed to characterize derangements of blood coagulation and to assess the effect of dual endothelin‐1 receptor antagonism in modulating hemostasis in this rare disorder.Methods
In a 10‐month recruitment period at a tertiary cardiology referral center, during which time there were over 14 000 outpatient consultations, consecutive subjects with Eisenmenger syndrome being considered for macitentan therapy (n = 9) and healthy volunteers (n = 9) were recruited. Plasma thrombin generation in platelet‐rich and platelet‐poor plasma was assessed by calibrated automated thrombography prior to and following therapy.Results
Median peak plasma thrombin generation was higher in platelet‐rich plasma obtained from Eisenmenger syndrome subjects relative to controls (median peak thrombin [25th–75th percentile]: 228.3 [206.5–258.6] nm vs. 169.9 [164.3–215.8] nm ), suggesting a critical mechanistic role for platelets in supporting abnormal hypercoagulability in Eisenmenger syndrome. Abnormal enhanced sensitivity to the anticoagulant activity of activated protein C was also observed in platelet‐rich plasma in Eisenmenger syndrome, suggesting that derangements of platelet activity may influence the activity of anticoagulant pathways in a manner that might promote bleeding in this disease state. Following 6 months of macitentan therapy, attenuations in the derangements in both procoagulant and anticoagulant pathways were observed.Conclusions
Abnormal platelet activity contributes to derangements in procoagulant and anticoagulant pathways in Eisenmenger syndrome. Therapies targeting the underlying vascular pathology appear to ameliorate these derangements and may represent a novel strategy for the management of the competing prothrombotic and hemorrhagic tendencies in this disorder.92.
93.
94.
N. Turgeon J.A. Fishman M. Doran N. Basgoz N.E. Tolkoff-Rubin A.B. Cosimi R.H. Rubin 《Transplant infectious disease》2000,2(1):2-10
Background: Although the primary treatment of symptomatic cytomegalovirus (CMV) disease in organ transplant recipients is successful in >90% of individuals, relapsing disease, particularly in those with primary infection, remains an important problem. Previously, we had observed that the rate of symptomatic recurrence was >60% in those with primary disease (seronegative for CMV prior to transplant), and approximately 20% in those who were seropositive prior to transplant. The present study was undertaken to determine whether a maintenance regimen of oral ganciclovir for 2–3 months added to the routine 14–21 days of intravenous ganciclovir would further prevent symptomatic CMV recurrence. Methods: From May 1995 until June 1998, all kidney and liver transplant recipients with confirmed tissue‐invasive CMV disease or CMV syndrome were treated with 14–21 days of intravenous ganciclovir (5 mg/kg b.i.d. with dose adjusted for renal dysfunction) followed by 2–3 months of oral ganciclovir (2 g daily). The incidence of recurrence of CMV disease and/or viremia during and after oral therapy was then determined over a mean follow‐up of 530.6 days. Results: Thirty‐seven patients, 19 kidney and 18 liver transplant recipients, were studied; 5 had biopsy‐proven tissue‐invasive disease (13.5) and 32 suffered a CMV syndrome (86.5). Twenty‐one of these patients (58.6) were seronegative for CMV prior to transplant and received an allograft from a seropositive donor (D+/R?). Overall, 10 patients (27.0) developed CMV recurrence. Eight of 21 patients who were D+/R? for CMV (38.1) developed recurrence as opposed to 2 of 16 patients with other serologic status (12.5) (P=0.14). Patients with recurrent CMV disease and/or viremia had a peak antigenemia assay titer during their initial CMV event of 319.2 positive cells/2 slides compared with 109.8 positive cells/2 slides for patients without recurrent CMV infection (P=0.14); the trend of having a higher peak antigenemia assay titer among patients who recurred occurred both in patients who were at risk of primary CMV infection (D+/R? for CMV) and in those who were not. Two patients developed recurrent infection with strains of CMV that were resistant to ganciclovir. Conclusions: This new therapeutic regimen of oral ganciclovir following intravenous ganciclovir slightly reduced the overall rate of recurrent CMV disease and/or viremia, but it still did not adequately prevent CMV recurrence in patients who are at risk of primary infection prior to transplant. Of particular concern, 2 patients with primary infection treated with this regimen developed ganciclovir‐resistant recurrent disease ( Note Presented in part at the American Society of Transplant Physicians Meeting, May 1999, Chicago, Illinois.
). 相似文献
). 相似文献
95.
JD Roberts JC Herkert J Rutberg SM Nikkel ACP Wiesfeld D Dooijes RM Gow JP van Tintelen MH Gollob 《Clinical genetics》2013,83(5):452-456
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease that predominantly affects the right ventricle and is associated with ventricular arrhythmias that may lead to sudden cardiac death. Mutations within at least seven separate genes have been identified to cause ARVC, however a genetic culprit remains elusive in approximately 50% of cases. Although negative genetic testing may be secondary to pathogenic mutations within undiscovered genes, an alternative explanation may be the presence of large deletions or duplications involving known genes. These large copy number variants may not be detected with standard clinical genetic testing which is presently limited to direct DNA sequencing. We describe two cases of ARVC possessing large deletions involving plakophilin‐2 (PKP2) identified with microarray analysis and/or multiplex ligation‐dependent probe amplification (MLPA) that would have been classified as genotype negative with standard clinical genetic testing. A deletion of the entire coding region of PKP2 excluding exon 1 was identified in patient 1 and his son. In patient 2, MLPA analysis of PKP2 revealed deletion of the entire gene with subsequent microarray analysis demonstrating a de novo 7.9 Mb deletion of chromosome 12p12.1p11.1. These findings support screening for large copy number variants in clinically suspected ARVC cases without clear disease causing mutations following initial sequencing analysis. 相似文献
96.
Anne M Fagan Rachel L Henson Yan Li Anna H Boerwinkle Chengjie Xiong Randall J Bateman Alison Goate Beau M Ances Eric Doran Bradley T Christian Florence Lai H Diana Rosas Nicole Schupf Sharon Krinsky-McHale Wayne Silverman Joseph H Lee William E Klunk Benjamin L Handen Ira T Lott 《Lancet neurology》2021,20(8):615-626
97.
98.
99.
Packham MA; Perry DW; Kinlough-Rathbone RL; Rand ML; Guccione MA; Evans RM; Mustard JF 《Blood》1985,65(3):564-570
Rabbit platelets were aggregated by adenosine diphosphate (ADP), allowed to deaggregate and then separated into density subpopulations by centrifugation through discontinuous Stractan density gradients. Although ADP causes little or no release of the contents of the amine storage granules of rabbit platelets, ADP caused a decrease in platelet density as compared with control platelets subjected to the same procedures except for exposure to ADP. The density change persisted for at least four hours. The apparent size of platelets stimulated with ADP increased initially, but returned to control values during a one-hour period. A similar decrease in platelet density was observed with an albumin density gradient. Under conditions in which aggregation did not occur in response to ADP with ethylenediaminetetraacetic acid (EDTA) in the medium, little or no decrease in platelet density was observed. Agglutination with polylysine did not change platelet density. Thus, not only agents such as thrombin and plasmin that cause the release of the contents of the platelet granules decrease platelet density, but ADP also has this effect. Platelets would be exposed to all of these stimuli during thromboembolic processes, and their effect on platelets may account for the decrease in platelet density observed previously in experiments with rabbits with indwelling aortic catheters. Agents that increase the concentration of cyclic AMP (cAMP) in platelets (PGE1, adenosine, dibutyryl cAMP, forskolin, and papaverine) also decreased platelet density. This effect persisted when the platelets were washed and resuspended in fresh medium and was also demonstrable in plasma. Platelet size was gradually increased by prostaglandin E1 (PGE1) which maintains platelets in a disc shape and does not cause the release of granule contents, indicating that the decrease in platelet density caused by PGE1 may be attributable to platelet swelling. 相似文献
100.
Tumor cells were isolated from the bone marrow of seven patients with multiple myeloma and from the peripheral blood of three patients with plasma cell leukemia using Ficoll-Hypaque (FH) density sedimentation followed by immune rosette depletion of T, myeloid, monocytoid, and natural killer (NK) cells. Enrichment to greater than or equal to 93% plasma cells was confirmed with Wright's-Giemsa staining, with intracytoplasmic immunoglobulin staining, and with staining using monoclonal antibodies (MoAbs) directed at B, T, myeloid, monocytoid, and myeloma antigens in indirect immunofluorescence assays. Myeloma cells neither proliferated nor secreted Ig in response to G/M-CSF, G- CSF, M-CSF, interleukin-1 alpha (IL-1 alpha), interleukin-1 beta (IL-1 beta), interleukin-2 (IL-2), or interleukin-4 (IL-4). Significant proliferation (SI greater than or equal to 3.0) was induced by interleukin-6 (IL-6) in six of ten patients (SI of 31 and 43 in two cases); and to interleukin-3 (IL-3) and interleukin-5 (IL-5), independently, in two patients each. Peak proliferation to IL-5 or IL-6 and to IL-3 occurred in cells pulsed with 3[H] thymidine at 24 and 48 hours, respectively; and proliferation to combinations of factors did not exceed that noted to IL-6 alone; Ig secretion was not documented under any culture conditions. Three myeloma-derived cell lines similarly studied demonstrated variable responses. The heterogeneity in the in vitro responses of myeloma cells and derived cell lines to exogenous growth factors enhances our understanding of abnormal plasma cell growth and may yield insight into the pathophysiology of plasma cell dyscrasias. 相似文献